Last reviewed · How we verify
DFN-02
DFN-02 is a novel formulation or delivery system designed to improve the pharmacokinetic profile or therapeutic efficacy of an active pharmaceutical ingredient.
At a glance
| Generic name | DFN-02 |
|---|---|
| Sponsor | Dr. Reddy's Laboratories Limited |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
DFN-02 represents a development-stage pharmaceutical candidate from Dr. Reddy's Laboratories in Phase 3 clinical trials. Without publicly disclosed mechanism details, the drug's exact molecular target and mode of action remain proprietary. The designation suggests it may involve a novel formulation technology or drug delivery approach.
Approved indications
Common side effects
Key clinical trials
- An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg) (PHASE2)
- DFN-02 Open Label Safety Study in Patients With Acute Migraine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DFN-02 CI brief — competitive landscape report
- DFN-02 updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI